Ignite Creation Date:
2025-12-24 @ 5:49 PM
Ignite Modification Date:
2025-12-28 @ 6:30 PM
Study NCT ID:
NCT00014768
Status:
TERMINATED
Last Update Posted:
2005-06-24
First Post:
2001-04-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Metabolic Effects of Pregnancy in Women With Cystic Fibrosis
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003550', 'term': 'Cystic Fibrosis'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D035583', 'term': 'Rare Diseases'}], 'ancestors': [{'id': 'D010182', 'term': 'Pancreatic Diseases'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}, {'id': 'D007232', 'term': 'Infant, Newborn, Diseases'}, {'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D005947', 'term': 'Glucose'}, {'id': 'D007328', 'term': 'Insulin'}, {'id': 'D007930', 'term': 'Leucine'}], 'ancestors': [{'id': 'D006601', 'term': 'Hexoses'}, {'id': 'D009005', 'term': 'Monosaccharides'}, {'id': 'D000073893', 'term': 'Sugars'}, {'id': 'D002241', 'term': 'Carbohydrates'}, {'id': 'D011384', 'term': 'Proinsulin'}, {'id': 'D061385', 'term': 'Insulins'}, {'id': 'D010187', 'term': 'Pancreatic Hormones'}, {'id': 'D036361', 'term': 'Peptide Hormones'}, {'id': 'D006728', 'term': 'Hormones'}, {'id': 'D006730', 'term': 'Hormones, Hormone Substitutes, and Hormone Antagonists'}, {'id': 'D010455', 'term': 'Peptides'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D000597', 'term': 'Amino Acids, Branched-Chain'}, {'id': 'D000596', 'term': 'Amino Acids'}, {'id': 'D000601', 'term': 'Amino Acids, Essential'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'observationalModel': 'NATURAL_HISTORY'}, 'enrollmentInfo': {'count': 36}}, 'statusModule': {'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2001-02'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2002-03', 'lastUpdateSubmitDate': '2005-06-23', 'studyFirstSubmitDate': '2001-04-10', 'studyFirstSubmitQcDate': '2001-04-10', 'lastUpdatePostDateStruct': {'date': '2005-06-24', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2001-04-11', 'type': 'ESTIMATED'}}, 'conditionsModule': {'keywords': ['cardiovascular and respiratory diseases', 'cystic fibrosis', 'genetic diseases and dysmorphic syndromes', 'rare disease'], 'conditions': ['Cystic Fibrosis']}, 'descriptionModule': {'briefSummary': 'OBJECTIVES: I. Compare the clinical status of pregnant vs non-pregnant women with cystic fibrosis.\n\nII. Determine glucose tolerance during each trimester of pregnancy in these women.\n\nIII. Evaluate peripheral insulin sensitivity in these women. IV. Evaluate whole body protein turnover and hepatic glucose production in these women.\n\nV. Determine resting energy expenditure in these women.', 'detailedDescription': 'PROTOCOL OUTLINE: Patients undergo a glucose tolerance test over 3 hours and a potassium body scan on day 1. Patients undergo an indirect calorimetry over 20 minutes on day 2. Patients receive stable-labeled leucine and stable-labeled glucose IV over 3 hours followed by insulin and glucose IV over 4-4.5 hours on day 2 using the hyperinsulinemic euglycemic clamp technique.\n\nBlood and breath samples are collected to measure glucose tolerance, peripheral insulin sensitivity, and whole body protein turnover. Hepatic glucose production is measured by mass spectrophotometry.\n\nPatients maintain a 3-day food journal before pregnancy, during each trimester, and after pregnancy.\n\nPatients undergo each study during the final 2 weeks of each trimester of pregnancy and then at 6 months post-partum.'}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'minimumAge': '0 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'PROTOCOL ENTRY CRITERIA:\n\n--Disease Characteristics--\n\n* Diagnosis of cystic fibrosis (CF) and pregnant OR Age, weight, and body mass index matched non-pregnant CF woman or pregnant non-CF woman\n* No infection with Burkholderia cepacia\n* FEV1 at least 60%\n\n--Prior/Concurrent Therapy--\n\n* At least 3 weeks since prior corticosteroids\n\n--Patient Characteristics--\n\n* Hepatic: No more than one transaminase level greater than 10% above normal\n\nOther:\n\nPregnant non-CF controls:\n\n* No cigarette smokers\n* No history of gestational diabetes mellitus\n* No type 1 or 2 diabetes\n* No other chronic illness'}, 'identificationModule': {'nctId': 'NCT00014768', 'briefTitle': 'Study of Metabolic Effects of Pregnancy in Women With Cystic Fibrosis', 'organization': {'class': 'NIH', 'fullName': 'National Center for Research Resources (NCRR)'}, 'orgStudyIdInfo': {'id': '199/15797'}, 'secondaryIdInfos': [{'id': 'UUSOM-IRB-7922-00'}]}, 'armsInterventionsModule': {'interventions': [{'name': 'glucose', 'type': 'DRUG'}, {'name': 'insulin', 'type': 'DRUG'}, {'name': 'leucine', 'type': 'DRUG'}]}, 'contactsLocationsModule': {'locations': [{'zip': '84132', 'city': 'Salt Lake City', 'state': 'Utah', 'country': 'United States', 'facility': 'University of Utah School of Medicine', 'geoPoint': {'lat': 40.76078, 'lon': -111.89105}}], 'overallOfficials': [{'name': 'Dana S. Hardin', 'role': 'STUDY_CHAIR', 'affiliation': 'University of Utah'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'National Center for Research Resources (NCRR)', 'class': 'NIH'}, 'collaborators': [{'name': 'University of Utah', 'class': 'OTHER'}]}}}